
Autonomous science. Founder and CEO at Potato (@readysetpotato). Former neuro at Brown, NIH, UCSD.
San Diego, CA
Joined October 2012
- Tweets1.9K
- Following1.1K
- Followers1.6K
- Likes8.2K
Pinned Tweet
We're building agents for autonomous science. Closed-loop, faster iterations, more discovery, less time. Massive human scientist + AI scientist collaboration.
Nick Edwards retweeted
Dreams of AI ending aging and of AI killing everyone through a purely in-silico-designed pandemic both rely on this fallacy.
It's understated here how much we lack ground truth data about what's happening inside of cells, or sensors to get that data. A single cell contains billions of protein molecules, across at least thousands of types, and at least trillions of interactions per second.
Think we solved protein folding? We've made enormous progress predicting static protein structures. But these proteins constantly change their conformation and interact with one another, often in ways we can't observe or model accurately.
Our best sensors capture a miniscule fraction of the activity in a living cell, orders of magnitude short of what's happening.
We actually lack the ability to perceive what's going on that would be required to build such a bottoms up simulation.
Let alone to scale this up to an organism or a global population.
We know we have an expanding universe not because of breakthroughs in theory or computation - but because Edwin Hubble got new data by looking through the Hooker telescope. Possibly the greatest mind, Einstein, was wrong in his model of the universe because he lacked the right instrument to bring him the right data.
That's where we are in biology. Our sensors are still so crude. No amount of pure computation or AI can build a perfect model.
We need an instrument revolution in biology, not just a computational or intelligence revolution. AI can generate hypotheses, but without sufficient ground truth data, we can't know whether our simulations are modeling reality.
If you had an exponential amount of compute you could solve simulate biology exactly and wouldn't need to run any experiments.
Some of you will think "of course, but that's an unrealistic assumption" and others will think "no, you need experiments even with that much compute. That's just How It's Done".
You would of course need evaluations once you have a solution, but you don't in principle need experiments to find it: Experiments are a way to save compute, dating from a time when it was much more expensive.
And I think the presentation is exponential but real systems aren't irreducibly exponential. AlphaFold worked, after all.
Largely agree with these thoughts, and have some perhaps discordant points to add.
- Solving biological diseases in the next few years will benefit mostly from the usefulness of the language models, substantially more than molecular ML.
- Proponents of the bitter lesson for biological models (not LLM) aren't wrong, just (possibly pathologically) too early. We don't have enough data, and the data we can collect quickly is probably not the right kind (we may get lucky with biology being easy, but it's usually not).
- I think just scaling models and public (passively accumulating) data is a cost ineffective direction (it's like scaling dense NNs on the internet). Today's model outputs are as good as GPT2. A single bioinformatician with linear regression, sometimes even without any additional data, can beat these models in many applications (people rarely benchmark AI advances against a simple Potts model). The most promising approaches for molecular models are innovating heavily on architecture (e.g. Baker Lab, Alphafold, etc). This may automate/speed up with LLMs.
- Few companies (hopefully Dyno included) are betting that we've triangulated enough pieces from multiple experimental channels to predict (with scale) how things translate in humans. Having worked on translating in vitro things to primates, I'm very cautious with the idea that current models, trained on current public data, can do anything more than manipulating already working solutions, either explicitly or through implicit remixing of what has worked. It may still work, but the underlying bets offer no specific reason why there is any epistemic risk advantage other than being "made with AI".
- Short term, there is more promise in combining molecular models with LLMs rather than scaling them. The two sources of lift in AI discovery elsewhere has been (1) Breaking Silos: AI synthesizes a bunch of knowledge/expertise that is rarely present in the same room (2) Data mining : AI pushes through volumes of data, with an intelligent eye, that humans or simple algorithms simply can't scale or adapt to. I'm curious what will come out of multimodal training of LLMs and biological data, which seems to be something the big players are pursuing. I think latent reasoning in the language (or better yet, + code) domain will reveal a lot more biology than scaling on nucleotides or proteins alone.
- My view is that the next opportunity of combining lab and AI will be massive-scale hypothesis testing with LLMs. Currently a multiplexed assay generally tries to test a handful of ideas because the humans are bandwidth limited in designing properly powered experiments. LLM's can scale this very well.
I have no doubt lots of good news will come on the impact of AI in biology in the next five years. I can't tell what paradigm will win, but my prediction is that it will not be the same paradigm imported from the LLM land (which will get a ton of funding anyways, because it's easy to pattern match for tech VCs).
There’s a really pronounced divide between people who are on the AI side of things and people who are on the biology side of things. Even among people working in AI, the divide persists based on where they’re focused.
The AI side, adherents of scaling laws and the bitter lesson, believe that AI getting better means AI being more capable of novel discoveries in medicine (that go beyond discovering new drugs in well understood targets or speeding up dry lab work etc).
The biology people think the idea of a bitter lesson in biology is kind of ridiculous and that regardless of AI’s capabilities it’s going to be at least 5-10 years until you could hope to reliably simulate human toxicology in silico (right now AI/ML can’t even reliably simulate in vivo studies like binding affinities or functional assays).
Even the most AI pilled of them, who will list all the areas that AI can reduce the time spent on various areas, don’t think the concept of AI discovering novel targets or generating new understanding of causal biology is realistic in the near term. Most, in fact, will readily characterize the assumption that even an “ASI” level model could find cures hidden in our current understanding (without expanding that understanding with significantly more biological data) as patently false.
This was a big part of why we wanted to experience it ourselves by using AI for a (very) small portion of what it can do in biology. It was both mind blowing and revealed some poignant insights into how different the problem of making AI better at something like coding is to the problems of biology.
Even if it unlocked the ability to generate new molecules at a stunning pace, its simulation (in silico) of binding only had 49% accuracy. And if we wanted to improve that, we’d need to feed it back the data from the lab - data that took about 30x as long to get as it took to generate the molecules. And these were tests in a test tube (turn of phrase), imagine how long it would take if we wanted to improve the model with data that required recruiting humans and monitoring their reactions.
Human biology is very complex, and adding a drug - especially a novel drug and doubly so for a novel drug acting on a novel mechanism - means mapping interactions that have nth-order-effects that we don’t have the data to predict. Virtual cells have made advancements enabled by AI, but the perturbations equate to a small fraction of the possible.
This is before you even get into curing disease, especially uniquely human diseases. Brain function involves cellular identities that are unique to humans, meaning animal studies are of little use.
How long does it take to understand what the side effects of chronic administration of a drug in humans are? AI can speed up analyzing the data, or designing the trial or even getting it approved…but it can’t make a 6 month trial complete in 3 months.
I think its important to point out that significant advancements can be made in AI that contribute to biology, while also being realistic about how much it speeds up something as complex as curing a specific cancer or diseases of the brain.
Nick Edwards retweeted
Yes real lab work takes time but if you continue to decouple design from execution it becomes a lot easier to optimize the execution steps. Lots of slow wet lab time comes from scientists explaining protocols to each other instead of well optimized handoffs. Rate limiting step is often humans chatting instead of cells growing
3/ Here’s how we’re connecting the pieces:
🧠 X-Scientist interprets camera views, computer screens, and instrument software to coordinate workflows.
🦾 X-Bot handles the physical interactions.
🚚 Mobile robots transport samples between stations.
Together, they connect protein production to experimental characterization.
Nick Edwards retweeted
Maybe controversial: the conversation about scientific bottlenecks is overfocused on automation. New measurement technologies deserve more attention. You could automate an assay that needs an entire facility – or you could REINVENT the assay so that it fits into just a few tubes.
Nick Edwards retweeted
Replying to @jakemintz @Suhail
important for people to not let these incidents convince them to accept even more Orwellian privacy invasions and controls
Enough with the hypotheslop. We need to scale experimentation
Ex-OpenAI science head @kevinweil explains why AI is making breakthroughs in math and coding but still struggles to discover new medicines:
"We now live in a world where it doesn’t matter whether you learned how to program, you can turn any idea you have into an actual working product in a few minutes."
"You got models solving Navier-Stokes and making progress on the Riemann hypothesis. But I think the biggest impact that AI will have for the world will be in sciences."
"These fields of science are so empirical. You don’t just think really hard about how you find a molecule that binds to the protein. You run experiments. If we want models to do that, the models need to see that data at scale."
"This is why there’s such a difference between model performance in mathematics and software engineering and model performance in science."
@warpsciences
This can’t be real. Therefore it must be real
Nick Edwards retweeted
💥 Introducing Warp Sciences, a new company applying AI and robotics to help the world develop new medicines faster.
We’ve raised a $215M Series A led by @lightspeedvp to bring frontier AI out of the browser and into the lab, and build scientific capacity here in America.
I co-founded Warp with my long-time friend @dpatil, FAIR co-founder @manohar_paluri, and drug hunter Sol Reisberg. The early team is full of incredible people like @bkspears9, who helped achieve Q>1 fusion at LLNL.
Autonomous labs are all the rage these days. We even had the CEO of Eli Lilly tweet about it this week.
But how do we get there? What does that future look like for scientists?
These are things I explored with Melissa Crisp, Senior Director at Eli Lilly and President of SLAS
The future looks even more exciting as we start to better integrate agents.
Think fully closed-loop processes with automated experimental design, execution, and analysis.
Check out episode 99 of the Once a Scientist podcast here:
youtube.com/watch?is=E2nkzjo…
a harbinger
We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development.
Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner.
Welcome @ashokaraj_ and team!
openai.com/index/openai-to-a…
Nick Edwards retweeted
I have a lot of respect for @nickcammarata and Goodfire, but I will add some thoughts from brains/neuroscience.
First, polysemanticity and distributed representations are ~widely~ seen in biological brains. (In some ways this is what I have spent my career on.) 1/
interpretability might be the most important scientific problem in the world right now, as I don't think we can solve alignment if we don't know what we're building. I think I have good news about it. I co-authored early work in mechanistic interpretability at OpenAI and came away pessimistic, because neural networks appeared to fold into arbitrary tangled knots. years later, I started openai's first large-scale automated interpretability project, finding about 2% of neurons legible with the primitive tools we had
with modern agentic tools and a much closer look, the picture looks totally different. the vast majority in models up to trillions of parameters are legible, and their circuits beautiful. many famous examples of tangled neurons turned out to be misunderstood. The roadblocks I expected mostly aren't there. I now think ambitious interpretability will be solved by the time we need it most, and possibly quite soon, as automated scientists keep improving. it may be a bitter lesson for interpretability: the simple thing, at absurd scale, works
already-clean.goodfire.com/
🥔
Emma's is the right take. The interesting question is not "can lab automation replace literally everything we do by hand?"
The interesting question is "what new experiments can we perform with automation that could never be done by hand?"
And for my money the best automation-only experiments are not going to be the ones that simply require lots of scale and replicates.
I'm more curious about the way AI enables rapid real-time adjustment of experimental conditions in response to data.
I want to see tight automation loops where an AI is making significant changes to the protocol 10 times a day. Not just changing the pipetting volumes on a few experimental inputs - totally refactoring a protocol the way that a human would.
It’s happening
New announcements by @mkratsios47
$2.4B in compute commitments from Genesis Mission partners
$100M investment from @NSF & @ENERGY for autonomous science ready instrumentation
BioHub / @ENERGY / @NIH partnership for data
Too many more to keep track this quickly.
It’s a lot!
Nick Edwards retweeted
New announcements by @mkratsios47
$2.4B in compute commitments from Genesis Mission partners
$100M investment from @NSF & @ENERGY for autonomous science ready instrumentation
BioHub / @ENERGY / @NIH partnership for data
Too many more to keep track this quickly.
It’s a lot!
Karl Deisseroth is also REALLY good at ping pong. Sometimes the world is unfair
BREAKING NEWS
The 2026 #NobelPrize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel “for their discoveries concerning light-gated ion channels and optogenetics.”























